VERAXA Biotech GmbH is a clinical-stage biotechnology company dedicated to combatting cancer through groundbreaking innovations. Focused on the development of next-generation antibody-based therapies, VERAXA applies proprietary antibody tools like functional antibody screening and conjugation platforms.

The company is advancing a robust drug pipeline that includes antibody-drug conjugates (ADCs) and innovative antibody formats. At the heart of VERAXA's screening platform is its high-throughput droplet-based microfluidic technology, allowing the screening of entire immune repertoires comprising millions of antibody-secreting cells.

Additionally, VERAXA's conjugation platform utilizes genetic code expansion and the fastest click-chemistry techniques, ensuring the precise and stable attachment of payloads to antibodies. Through these advanced methodologies, VERAXA Biotech is at the forefront of developing cutting-edge solutions for cancer therapy.